



SAVE THE DATE

BioInvent KOL Call: BI-1206 for Relapsed or Refractory Non-Hodgkin's Lymphoma

Hosted by BioInvent (STO: BINV)

The event will feature a presentation by **renowned lymphoma expert Mats Jerkeman, MD, Lund University**, who will discuss the current treatment landscape, and unmet medical need for patients with relapsed or refractory Non-Hodgkin's Lymphoma for whom current treatment options are very limited. Dr Jerkeman will also discuss his experience in treating these patients with BioInvent's anti-FcγRIIB antibody, BI-1206, a novel monoclonal antibody that specifically targets the antibody "brakes" to help overcome resistance to rituximab.

BioInvent's Management team will also give an update on the ongoing Phase I/IIa trial of BI-1206 in combination with rituximab and BioInvent's partner CASI Pharmaceuticals (NASDAQ: CASI) will provide an update on the development plan and potential for BI-1206 in China. Dr. Jerkeman and senior members of the BioInvent and CASI management teams will be available to answer questions following the formal presentations.

Thursday, January 28th

11:30 AM - 12:30 PM EST

[REGISTER HERE](#)

For those unable to listen at this time, a replay of the call will be available by clicking [here](#).

Q&A Information

If you would like to ask a question during the live Q&A, please submit your request via email.

[Email Q&A](#)

KOL Biography



Mats Jerkeman, MD

Dr. Mats Jerkeman is Professor in Clinical Oncology at Lund University, Sweden. His research focus is all possible aspects of malignant lymphomas, aiming for the improvement of the quality of life and survival of these patients.

Dr. Jerkeman is the coordinator of several ongoing clinical trials in diffuse large B-cell lymphoma and mantle cell lymphoma. He also serves as Chairman of the Nordic Lymphoma Group, Editor of ESMO Guidelines/Lymphoma and as coordinator of the Swedish Lymphoma Register for many years.



250 West 55th Street, Suite 3401
New York, NY 10019

[E: contact@lifesciadvisors.com](mailto:contact@lifesciadvisors.com)

Copyright © 2020 LifeSci Advisors, LLC, All rights reserved.

This message contains confidential and proprietary information and is intended only for the individual named. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if you have received this email by mistake and delete this email from your system. All market prices, data and other information contained in this email are not warranted as to completeness or accuracy and are subject to change without notice. Any comments or statements made herein do not necessarily reflect the views of LifeSci Advisors, LLC, its affiliates, subsidiaries or agents. The message is not intended as an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Before opening any attachments please check them for viruses and defects.